Acumen Pharmaceuticals Inc. Common Stock (ABOS)

FairStock Score: 57/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable competitive advantages, honest accounting, and a margin of safety. Acumen fails the first test. It is a clinical-stage biotech with no revenue in any filed period I can see. Fiscal 2025 net loss was $121.3 million, wider than fiscal 2024's $102.3 million and fiscal 2023's $52.4 million. In fiscal Q2 2026, the quarter ended 2026-06-30, net loss was $32.7 million; fiscal Q1 2026 lost $20.7 million; fiscal Q3 2025 lost $26.5 million. That is a lot of red ink for a company with a $131.3 million market cap at the 2026-10-13 close of $1.82. Trailing twelve-month free cash flow was negative $91.8 million, a negative 69.9% FCF yield on that market cap, so cash burn is the central risk. The FairStock ratios show P/B 2.30, ROE -120.5%, ROCE -45.77%, Piotroski 0/9, and Altman Z-score -3.98. Those are not the marks of financial strength. Debt-to-equity of 0.55 is not the main problem; the lack of revenue and persistent losses are. The potential asset is sabirnetug (ACU193), in Phase 2 ALTITUDE-AD for Alzheimer's, plus a Halozyme collaboration for a subcutaneous formulation. If it works, that could be valuable. But there is no approved product, no commercial moat, and no demonstrated pricing power. The Lynch category is none because it has lost money in each of the last four years. At $1.82, the price is a speculative option on clinical data, not a Graham-style bargain. I would need trial validation and a much clearer financing runway before calling this a business rather than a lottery ticket.

In plain English: Acumen Pharmaceuticals is a small clinical-stage biotech working on an experimental Alzheimer's treatment called sabirnetug. It has no product sales and is losing money heavily, with losses in every recent quarter and fiscal year shown. At $1.82, the price is not supported by current profits or sales; it looks speculative and depends mostly on future trial results, while the business numbers look weak.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer